期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 10, 期 6, 页码 967-981出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560902834961
关键词
breast cancer; chemotherapy; endocrine therapy; metastatic disease; targeted agents
Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic advances. Recently there has been progress extending the range of available cytotoxic chemotherapy drugs and optimizing their scheduling. In addition, a greater understanding of tumor biology has led to the development of a number of targeted therapies. Several of these newer agents, such as trastuzumab, lapatinib and bevacizumab, have demonstrated activity in combination with chemotherapy and have improved the prognosis of patients with MBC. We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据